Founded Year

2014

Stage

Series F | Alive

Total Raised

$1.353B

Last Raised

$254M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-81 points in the past 30 days

About Freenome

Freenome focuses on early cancer detection through blood tests. The company's main offerings include next-generation blood tests that utilize multiomics technology and machine learning to identify cancer in its early stages. Freenome primarily serves the healthcare sector with a focus on improving cancer screening and detection. It was founded in 2014 and is based in Brisbane, California.

Headquarters Location

3300 Marina Boulevard 5th Floor

Brisbane, California, 94005,

United States

650-446-6630

Loading...

ESPs containing Freenome

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…

Freenome named as Challenger among 15 other companies, including QIAGEN, Exact Sciences, and Caris Life Sciences.

Loading...

Research containing Freenome

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Freenome in 9 CB Insights research briefs, most recently on Jan 16, 2025.

Expert Collections containing Freenome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Freenome is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,276 items

A

AI 100 (All Winners 2018-2025)

99 items

Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

D

Digital Health 50

300 items

The most promising digital health startups transforming the healthcare industry

D

Digital Health

11,408 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

Freenome Patents

Freenome has filed 22 patents.

The 3 most popular patent topics include:

  • molecular biology
  • oncology
  • cancer screening
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/18/2023

3/11/2025

Clusters of differentiation, Blood tests, Blood, Immunology, Cell biology

Grant

Application Date

8/18/2023

Grant Date

3/11/2025

Title

Related Topics

Clusters of differentiation, Blood tests, Blood, Immunology, Cell biology

Status

Grant

Latest Freenome News

Global Virtual Biopsy Market To Reach $1.12 Billion By 2029 With A Growth Rate Of 12.0%.

Jun 20, 2025

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, June 20, 2025 / EINPresswire.com / -- What Is The Growth Trajectory Of The Virtual Biopsy Market The virtual biopsy market size has grown rapidly in recent years. It will grow from $0.63 billion in 2024 to $0.71 billion in 2025 at a compound annual growth rate CAGR of 12.2%. The growth in the historic period can be attributed to increasing demand for non-invasive diagnostic methods, growing preference for early disease detection, rising efficiency in medical imaging software, increasing patient convenience and comfort, and rising availability of telemedicine services. Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=24424&type=smp What Is The Projected Growth Rate And Market Size Of The Global Virtual Biopsy Market? The virtual biopsy market size is expected to see significant expansion in the next few years, as it is forecasted to grow to $1.12 billion in 2029 at a compound annual growth rate CAGR of 12.0%. This growth in the forecast period can primarily be attributed to a growing focus on cost-effective healthcare solutions, a shift towards preventive healthcare measures, increasing demand for personalized medicine, rising demand for minimally invasive cancer treatments, and the growing importance of precision oncology. What Is Driving The Growth Of The Virtual Biopsy Market? Another significant driver of the virtual biopsy market is the rising prevalence of oncological disorders. These health conditions, related to cancer, involve abnormal cells growing and spreading in the body. The increasing prevalence of such disorders primarily stems from lifestyle changes such as poor diet, physical inactivity, tobacco use, and increasing exposure to environmental pollutants. What Are The Emerging Trends In The Virtual Biopsy Market? Emerging trends framing the forecast period include the development of imaging sensors, multimodal biopsy techniques, integration with robotics for precision, innovation in non-invasive biomarker detection, and the coupling with three-dimensional 3D visualization tools. Virtual biopsy enhances the diagnosis and monitoring of these conditions by offering non-invasive, real-time imaging insights, reducing the need for traditional tissue biopsies while improving accuracy and patient safety. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia rose to 160,570 in 2022, marking an increase of 3,789 cases compared to 156,781 in 2021. Therefore, the rising prevalence of oncological disorders bolsters the growth of the virtual biopsy market. Order Your Report Now For A Swift Delivery: https://www.thebusinessresearchcompany.com/report/virtual-biopsy-global-market-report Which Key Industry Players Are Contributing To The Growth Of The Virtual Biopsy Market? Prominent companies operating in the virtual biopsy market include Canon Inc., Siemens Healthineers AG, GE Healthcare, Quest Diagnostics Incorporated, Olympus Corporation, Hologic Inc., Illumina Inc., Guardant Health Inc., Esaote S.p.A, Samsung Medison Co Ltd., Telix Pharmaceuticals Limited, Freenome Holdings Inc., Perspectum Ltd., QUIBIM S.L, IQ-AI Limited, BrainSpec Inc., Oncoustics Inc, ImageBiopsy Lab GmbH, AI Metrics LLC, and Deep Bio Inc. These industry leaders are focusing on developing technologically advanced solutions and obtaining clearances like the magnetic resonance spectroscopy MRS platform to enhance non-invasive diagnostic accuracy and provide real-time analysis for early disease detection and personalized treatment. How Is The Global Virtual Biopsy Market Segmented? The virtual biopsy market report segments the market by target therapeutic areas, cancer targeted, imaging technologies, and end users into the following subsegments by various disorders and conditions. What Are The Regional Insights Into The Virtual Biopsy Market? By geography, North America was the largest region in this market in 2024, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. Browse Through More Similar Reports By The Business Research Company Virtual Reality Devices Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/virtual-reality-devices-global-market-report Virtual Reality Services Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/virtual-reality-services-global-market-report Smart Biopsy Devices Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/smart-biopsy-devices-global-market-report The Business Research Company truly understands the pulse of your target domains. With over 15000+ reports from 27 industries covering 60+ geographies, we offer comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the expertise of in-depth secondary research, and unique insights from industry leaders, we ensure you stay ahead in your game. Contact us at: The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info Follow us on: LinkedIn: https://in.linkedin.com/company/the-business-research-company YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Freenome Frequently Asked Questions (FAQ)

  • When was Freenome founded?

    Freenome was founded in 2014.

  • Where is Freenome's headquarters?

    Freenome's headquarters is located at 3300 Marina Boulevard, Brisbane.

  • What is Freenome's latest funding round?

    Freenome's latest funding round is Series F.

  • How much did Freenome raise?

    Freenome raised a total of $1.353B.

  • Who are the investors of Freenome?

    Investors of Freenome include Andreessen Horowitz, DCVC, Section 32, RA Capital Management, Polaris Partners and 50 more.

  • Who are Freenome's competitors?

    Competitors of Freenome include 20/20 BioLabs, Owlstone Medical, BioTwin, GRAIL, Diagu and 7 more.

Loading...

Compare Freenome to Competitors

20/20 BioLabs Logo
20/20 BioLabs

20/20 BioLabs provides diagnostics for the healthcare sector, focusing on the detection and prevention of cancers and chronic diseases. The company offers laboratory-based blood tests that utilize machine learning algorithms to analyze real-world data, providing testing solutions. 20/20 BioLabs serves individuals seeking health management and healthcare providers in need of diagnostic tools. 20/20 BioLabs was formerly known as 20/20 GeneSystems. It was founded in 2000 and is based in Gaithersburg, Maryland.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.

O
OncoTAB

OncoTAb specializes in biotechnology with a focus on cancer diagnostic solutions. The company offers Agkura® Personal Score, a non-invasive blood test that measures tumor protein levels to aid in breast cancer detection. This test serves as a supplemental tool to mammography, which often misses cancers in women with dense breast tissue. It is based in Charlotte, North Carolina.

L
Liquid Genomics

Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.

Accuragen Logo
Accuragen

AccuraGen develops liquid biopsy technology for the cancer diagnostics industry. The company provides services related to DNA and RNA sequencing to assist in treatment plans for cancer patients, emphasizing non-invasive diagnostic methods. AccuraGen serves the healthcare sector, particularly in oncology. It is based in Menlo Park, California.

A
Artificial Intelligence Expert

Artificial Intelligence Expert focuses on AI technologies related to early detection of cancer within the healthcare sector. The company provides tests that can identify various types of cancer with reported accuracy rates. It is based in Cluj-Napoca, Romania.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.